Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL HYPERURICEMIA DRUGS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL HYPERURICEMIA DRUGS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY BASED MODELLING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL HYPERURICEMIA DRUGS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES MODEL
5.3 STRATEGIC INITIATIVES
6 REGULATORY FRAMEWORK
7 PIPELINE ANALYSIS
7.1 PHASE I
7.2 PHASE II
7.3 PHASE III
7.4 PRE-CLINICAL
8 EPIDEMIOLOGY
9 GLOBAL HYPERURICEMIA DRUGS MARKET, BY TREATMENT
9.1 OVERVIEW
9.2 MARKETED DRUGS
9.2.1 XANTHINE OXIDASE INHIBITORS
9.2.1.1. ALLOPURINOL
9.2.1.1.1. MARKET VALUE (USD MN)
9.2.1.1.2. MARKET VOLUME (SU)
9.2.1.1.3. AVERAGE SELLING PRICE (USD)
9.2.1.2. FEBUXOSTAT
9.2.1.2.1. MARKET VALUE (USD MN)
9.2.1.2.2. MARKET VOLUME (SU)
9.2.1.2.3. AVERAGE SELLING PRICE (USD)
9.2.1.3. TOPIROXOSTAT
9.2.1.3.1. MARKET VALUE (USD MN)
9.2.1.3.2. MARKET VOLUME (SU)
9.2.1.3.3. AVERAGE SELLING PRICE (USD)
9.2.2 URICOSURICS
9.2.2.1. BENZOBROMARONE
9.2.2.1.1. MARKET VALUE (USD MN)
9.2.2.1.2. MARKET VOLUME (SU)
9.2.2.1.3. AVERAGE SELLING PRICE (USD)
9.2.2.2. PROBENECID
9.2.2.2.1. MARKET VALUE (USD MN)
9.2.2.2.2. MARKET VOLUME (SU)
9.2.2.2.3. AVERAGE SELLING PRICE (USD)
9.2.2.3. SULFINPYRAZONE
9.2.2.3.1. MARKET VALUE (USD MN)
9.2.2.3.2. MARKET VOLUME (SU)
9.2.2.3.3. AVERAGE SELLING PRICE (USD)
9.2.2.4. LESINURAD
9.2.2.4.1. MARKET VALUE (USD MN)
9.2.2.4.2. MARKET VOLUME (SU)
9.2.2.4.3. AVERAGE SELLING PRICE (USD)
9.2.3 URATE OXIDASE ENZYME (PEGLOTICASE)
9.2.3.1. MARKET VALUE (USD MN)
9.2.3.2. MARKET VOLUME (SU)
9.2.3.3. AVERAGE SELLING PRICE (USD)
9.2.4 NON STEROIDAL ANTI- INFLAMMATORY DRUGS (NSAIDS)
9.2.4.1. INDOMETHACIN
9.2.4.1.1. MARKET VALUE (USD MN)
9.2.4.1.2. MARKET VOLUME (SU)
9.2.4.1.3. AVERAGE SELLING PRICE (USD)
9.2.4.2. NAPROXEN
9.2.4.2.1. MARKET VALUE (USD MN)
9.2.4.2.2. MARKET VOLUME (SU)
9.2.4.2.3. AVERAGE SELLING PRICE (USD)
9.2.4.3. IBUPROFEN
9.2.4.3.1. MARKET VALUE (USD MN)
9.2.4.3.2. MARKET VOLUME (SU)
9.2.4.3.3. AVERAGE SELLING PRICE (USD)
9.2.4.4. SULINDIC
9.2.4.4.1. MARKET VALUE (USD MN)
9.2.4.4.2. MARKET VOLUME (SU)
9.2.4.4.3. AVERAGE SELLING PRICE (USD)
9.2.4.5. KETOPROFEN
9.2.4.5.1. MARKET VALUE (USD MN)
9.2.4.5.2. MARKET VOLUME (SU)
9.2.4.5.3. AVERAGE SELLING PRICE (USD)
9.2.4.6. OTHERS
9.2.5 COLCHICINE
9.2.5.1. MARKET VALUE (USD MN)
9.2.5.2. MARKET VOLUME (SU)
9.2.5.3. AVERAGE SELLING PRICE (USD)
9.2.6 CORTICOSTEROIDS
9.2.6.1. PREDNISONE
9.2.6.1.1. MARKET VALUE (USD MN)
9.2.6.1.2. MARKET VOLUME (SU)
9.2.6.1.3. AVERAGE SELLING PRICE (USD)
9.2.6.2. TRIAMCINOLONE
9.2.6.2.1. MARKET VALUE (USD MN)
9.2.6.2.2. MARKET VOLUME (SU)
9.2.6.2.3. AVERAGE SELLING PRICE (USD)
9.2.6.3. OTHERS
9.2.7 PROBIOTICS
9.2.7.1. MARKET VALUE (USD MN)
9.2.7.2. MARKET VOLUME (SU)
9.2.7.3. AVERAGE SELLING PRICE (USD)
9.2.8 OTHERS
9.3 PIPELINE DRUGS
9.3.1 URICOSURICS
9.3.1.1. VERINURAD
9.3.1.2. ARHALOFENATE
9.3.1.3. TRANILAST
9.3.1.4. LEVOTIFISOPAM
9.3.1.5. OTHERS
9.3.2 PNP INHIBITORS
9.3.2.1. ULODESINE
9.3.2.2. OTHERS
9.3.3 DUAL INHIBITORS
9.3.3.1. RLBN1001
9.3.3.2. OTHERS
9.3.4 OTHERS
10 GLOBAL HYPERURICEMIA DRUGS MARKET, BY DISEASE TYPE
10.1 OVERVIEW
10.2 ASYMPTOMATIC HYPERURICEMIA
10.2.1 BRANDED
10.2.2 GENERICS
10.3 SYMPTOMATIC HYPERURICEMIA
10.3.1 GOUT
10.3.1.1. BRANDED
10.3.1.2. GENERICS
10.3.2 TOPHACEOUS GOUT
10.3.2.1. BRANDED
10.3.2.2. GENERICS
10.3.3 KIDNEY STONES
10.3.3.1. BRANDED
10.3.3.2. GENERICS
11 GLOBAL HYPERURICEMIA DRUGS MARKET, BY DRUG TYPE
11.1 OVERVIEW
11.2 BRANDED
11.2.1 ZYLOPRIM
11.2.2 PROMETHEUS
11.2.3 ALOPRIM
11.2.4 COLCRYS
11.2.5 GLOPERBA
11.2.6 ULORIC
11.2.7 KRYSTEXXA
11.2.8 OTHERS
11.3 GENERICS
12 GLOBAL HYPERURICEMIA DRUGS MARKET, BY MODE OF PURCHASE
12.1 OVERVIEW
12.2 OVER THE COUNTER
12.3 PRESCRIPTION
13 GLOBAL HYPERURICEMIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 PARENTERAL
13.2.1 SUBCUTANEOUS
13.2.2 INTRAMUSCULAR
13.2.3 INTRAVENOUS
13.3 ORAL
13.3.1 TABLETS
13.3.2 CAPSULES
13.3.3 OTHERS
13.4 TOPICAL
14 GLOBAL HYPERURICEMIA DRUGS MARKET, BY AGE GROUP
14.1 OVERVIEW
14.2 PEDIATRICS
14.3 ADULTS
14.3.1 MALE
14.3.2 FEMALE
14.4 GERIATRIC
14.4.1 MALE
14.4.2 FEMALE
15 GLOBAL HYPERURICEMIA DRUGS MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECIALITY CLINICS
15.4 HOMECARE
15.5 ACADEMIC & RESEARCH INSTITUTES
15.6 OTHERS
16 U.S. DENTAL DEVICES AND CONSUMABLES MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 HOSPITAL PHARMACY
16.2.1 BRANDED
16.2.2 GENERIC
16.3 RETAIL PHARMACY
16.3.1 BRANDED
16.3.2 GENERIC
16.4 ONLINE PHARMACY
16.4.1 BRANDED
16.4.2 GENERIC
16.5 OTHERS
17 GLOBAL HYPERURICEMIA DRUGS MARKET, BY REGION
17.1 GLOBAL HYPERURICEMIA DRUGS MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
17.2 NORTH AMERICA
17.2.1 U.S.
17.2.1.1. U.S HYPERURICEMIA DRUGS MARKET, BY TYPE
17.2.1.2. U.S HYPERURICEMIA DRUGS MARKET, BY DISEASE TYPE
17.2.1.3. U.S HYPERURICEMIA DRUGS MARKET, BY DRUG TYPE
17.2.1.4. U.S HYPERURICEMIA DRUGS MARKET, BY MODE OF PURCHASE
17.2.1.5. U.S HYPERURICEMIA DRUGS MARKET, BY ROUTE OF ADMINISTARTION
17.2.1.6. U.S HYPERURICEMIA DRUGS MARKET, BY AGE GROUP
17.2.1.7. U.S HYPERURICEMIA DRUGS MARKET, BY END USER
17.2.1.8. U.S HYPERURICEMIA DRUGS MARKET, BY DISTRIBUTION CHANNELS
17.2.2 CANADA
17.2.3 MEXICO
17.3 EUROPE
17.3.1 GERMANY
17.3.2 FRANCE
17.3.3 U.K.
17.3.4 FINLAND
17.3.5 DENMARK
17.3.6 NORWAY
17.3.7 POLAND
17.3.8 ITALY
17.3.9 SPAIN
17.3.10 RUSSIA
17.3.11 TURKEY
17.3.12 BELGIUM
17.3.13 NETHERLANDS
17.3.14 SWITZERLAND
17.3.15 SWEDEN
17.3.16 REST OF EUROPE
17.4 ASIA-PACIFIC
17.4.1 JAPAN
17.4.2 CHINA
17.4.3 SOUTH KOREA
17.4.4 INDIA
17.4.5 SINGAPORE
17.4.6 THAILAND
17.4.7 INDONESIA
17.4.8 MALAYSIA
17.4.9 PHILIPPINES
17.4.10 AUSTRALIA
17.4.11 NEW ZEALAND
17.4.12 VIETNAM
17.4.13 TAIWAN
17.4.14 REST OF ASIA-PACIFIC
17.5 SOUTH AMERICA
17.5.1 BRZIL
17.5.2 ARGENTINA
17.5.3 REST OF SOUTH AMERICA
17.6 MIDDLE EAST AND AFRICA
17.6.1 SOUTH AFRICA
17.6.2 SAUDI ARABIA
17.6.3 UAE
17.6.4 EGYPT
17.6.5 KUWAIT
17.6.6 OMAN
17.6.7 ISRAEL
17.6.8 BAHRAIN
17.6.9 REST OF MIDDLE EAST AND AFRICA
17.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
18 GLOBAL HYPERURICEMIA DRUGS MARKET, SWOT AND DBMR ANALYSIS
19 GLOBAL HYPERURICEMIA DRUGS MARKET, COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: GLOBAL
19.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
19.3 COMPANY SHARE ANALYSIS: EUROPE
19.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
19.5 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
19.6 COMPANY SHARE ANALYSIS: SOUTH AMERICA
19.7 MERGERS & ACQUISITIONS
19.8 NEW PRODUCT DEVELOPMENT & APPROVALS
19.9 EXPANSIONS
19.1 REGULATORY CHANGES
19.11 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
20 GLOBAL HYPERURICEMIA DRUGS MARKET, COMPANY PROFILE
20.1 TAKEDA PHARMACEUTICALS
20.1.1 COMPANY OVERVIEW
20.1.2 REVENUE ANALYSIS
20.1.3 GEOGRAPHIC PRESENCE
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.2 GLAXOSMITHKNLINE PLC
20.2.1 COMPANY OVERVIEW
20.2.2 REVENUE ANALYSIS
20.2.3 GEOGRAPHIC PRESENCE
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.3 PFIZER
20.3.1 COMPANY OVERVIEW
20.3.2 REVENUE ANALYSIS
20.3.3 GEOGRAPHIC PRESENCE
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENTS
20.4 DR REDDY'S LABORATORIES
20.4.1 COMPANY OVERVIEW
20.4.2 REVENUE ANALYSIS
20.4.3 GEOGRAPHIC PRESENCE
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENTS
20.5 ALEMBIC PHARMACEUTICALS
20.5.1 COMPANY OVERVIEW
20.5.2 REVENUE ANALYSIS
20.5.3 GEOGRAPHIC PRESENCE
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENTS
20.6 SUN PHARMACEUTICALS
20.6.1 COMPANY OVERVIEW
20.6.2 REVENUE ANALYSIS
20.6.3 GEOGRAPHIC PRESENCE
20.6.4 PRODUCT PORTFOLIO
20.6.5 RECENT DEVELOPMENTS
20.7 LANNETT
20.7.1 COMPANY OVERVIEW
20.7.2 REVENUE ANALYSIS
20.7.3 GEOGRAPHIC PRESENCE
20.7.4 PRODUCT PORTFOLIO
20.7.5 RECENT DEVELOPMENTS
20.8 EISAI CO., LTD
20.8.1 COMPANY OVERVIEW
20.8.2 REVENUE ANALYSIS
20.8.3 GEOGRAPHIC PRESENCE
20.8.4 PRODUCT PORTFOLIO
20.8.5 RECENT DEVELOPMENTS
20.9 MERCK & CO., INC
20.9.1 COMPANY OVERVIEW
20.9.2 REVENUE ANALYSIS
20.9.3 GEOGRAPHIC PRESENCE
20.9.4 PRODUCT PORTFOLIO
20.9.5 RECENT DEVELOPMENTS
20.1 MARLEX PHARMACEUTICALS INC
20.10.1 COMPANY OVERVIEW
20.10.2 REVENUE ANALYSIS
20.10.3 GEOGRAPHIC PRESENCE
20.10.4 PRODUCT PORTFOLIO
20.10.5 RECENT DEVELOPMENTS
20.11 NOVARTIS
20.11.1 COMPANY OVERVIEW
20.11.2 REVENUE ANALYSIS
20.11.3 GEOGRAPHIC PRESENCE
20.11.4 PRODUCT PORTFOLIO
20.11.5 RECENT DEVELOPMENTS
20.12 APOTEX CORPORATION
20.12.1 COMPANY OVERVIEW
20.12.2 REVENUE ANALYSIS
20.12.3 GEOGRAPHIC PRESENCE
20.12.4 PRODUCT PORTFOLIO
20.12.5 RECENT DEVELOPMENTS
20.13 HORIZON PHARMACEUTICALS
20.13.1 COMPANY OVERVIEW
20.13.2 REVENUE ANALYSIS
20.13.3 GEOGRAPHIC PRESENCE
20.13.4 PRODUCT PORTFOLIO
20.13.5 RECENT DEVELOPMENTS
20.14 ASTRAZENECA
20.14.1 COMPANY OVERVIEW
20.14.2 REVENUE ANALYSIS
20.14.3 GEOGRAPHIC PRESENCE
20.14.4 PRODUCT PORTFOLIO
20.14.5 RECENT DEVELOPMENTS
20.15 KISSEI PHARMACEUTICALS
20.15.1 COMPANY OVERVIEW
20.15.2 REVENUE ANALYSIS
20.15.3 GEOGRAPHIC PRESENCE
20.15.4 PRODUCT PORTFOLIO
20.15.5 RECENT DEVELOPMENTS
20.16 CIPLA, INC
20.16.1 COMPANY OVERVIEW
20.16.2 REVENUE ANALYSIS
20.16.3 GEOGRAPHIC PRESENCE
20.16.4 PRODUCT PORTFOLIO
20.16.5 RECENT DEVELOPMENTS
20.17 TEVA PHARMACEUTICALS
20.17.1 COMPANY OVERVIEW
20.17.2 REVENUE ANALYSIS
20.17.3 GEOGRAPHIC PRESENCE
20.17.4 PRODUCT PORTFOLIO
20.17.5 RECENT DEVELOPMENTS
20.18 BRISTOL MEYERS SQUIBB
20.18.1 COMPANY OVERVIEW
20.18.2 REVENUE ANALYSIS
20.18.3 GEOGRAPHIC PRESENCE
20.18.4 PRODUCT PORTFOLIO
20.18.5 RECENT DEVELOPMENTS
20.19 LUPIN PHARMACEUTICALS
20.19.1 COMPANY OVERVIEW
20.19.2 REVENUE ANALYSIS
20.19.3 GEOGRAPHIC PRESENCE
20.19.4 PRODUCT PORTFOLIO
20.19.5 RECENT DEVELOPMENTS
20.2 CADILA HEALTHCARE
20.20.1 COMPANY OVERVIEW
20.20.2 REVENUE ANALYSIS
20.20.3 GEOGRAPHIC PRESENCE
20.20.4 PRODUCT PORTFOLIO
20.20.5 RECENT DEVELOPMENTS
20.21 ELI LILLY AND COMPANY
20.21.1 COMPANY OVERVIEW
20.21.2 REVENUE ANALYSIS
20.21.3 GEOGRAPHIC PRESENCE
20.21.4 PRODUCT PORTFOLIO
20.21.5 RECENT DEVELOPMENTS
20.22 CAMBER PHARMACEUTICALS
20.22.1 COMPANY OVERVIEW
20.22.2 REVENUE ANALYSIS
20.22.3 GEOGRAPHIC PRESENCE
20.22.4 PRODUCT PORTFOLIO
20.22.5 RECENT DEVELOPMENTS
20.23 GLENMARK PHARMACEUTICALS
20.23.1 COMPANY OVERVIEW
20.23.2 REVENUE ANALYSIS
20.23.3 GEOGRAPHIC PRESENCE
20.23.4 PRODUCT PORTFOLIO
20.23.5 RECENT DEVELOPMENTS
20.24 SCIEGEN PHARMACEUTICALS, INC.
20.24.1 COMPANY OVERVIEW
20.24.2 REVENUE ANALYSIS
20.24.3 GEOGRAPHIC PRESENCE
20.24.4 PRODUCT PORTFOLIO
20.24.5 RECENT DEVELOPMENTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
21 RELATED REPORTS
22 CONCLUSION
23 QUESTIONNAIRE
24 ABOUT DATA BRIDGE MARKET RESEARCH
